← All companies ← BCS Manual BEKE → ← BBNX Medical Devices & Equipment BDX →
BDMD, Baird Medical Investment Holdings Ltd
We have identified the relevant risk characteristics of its customers and the related receivables and other receivables which include size, type of the products we provide, or a combination of these characteristics.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is MWA needles (76%) and MWA therapeutic apparatus (24%).
- Situation
- Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Gross margin has run about 84% and operating margin about 38% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −114% to 41% — on a steadier 84% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Read this kind of business on the installed base and what follows it. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has run high across the record (median 27%, above 15% in 2 of 3 years), though buybacks and expensed R&D and brands shrink the capital base, so the figure overstates the underlying economics. Owner earnings, the cash-based check, have been thin too. Whether these returns reflect real pricing power or an accounting artifact is the judgment the 10-K is for.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 20-F →MWA needles is 76% of revenue, with MWA therapeutic apparatus the other meaningful line at 24%.
- MWA needles76%$17M
- MWA therapeutic apparatus24%$5M
From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2022–2025
realized figures from each filing · older years to the left| 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| $35M | $31M | $37M | $23M | $23M | RevenueRevenue |
| 80% | 87% | 88% | 84% | 84% | Gross marginGross mgn |
| $14M | $12M | $15M | ($26M) | ($26M) | Operating incomeOp. inc. |
| 38.8% | 37.7% | 41.4% | −113.7% | −113.7% | Operating marginOp. mgn |
| $13M | $11M | $13M | ($28M) | ($28M) | Net incomeNet inc. |
| 12% | 14% | 11% | — | — | Effective tax rateTax rate |
| Cash flow & returns | |||||
| $486K | ($1M) | ($6M) | ($1M) | ($1M) | Operating cash flowOp. cash |
| $916K | $1M | $1M | $1M | $1M | DepreciationDeprec. |
| ($13M) | ($13M) | ($20M) | $25M | $25M | Working capital & otherWC & other |
| $6M | $3M | $3M | $42K | $42K | CapexCapex |
| 16.8% | 8.4% | 7.7% | 0.2% | 0.2% | Capex / revenueCapex/rev |
| ($5M) | ($4M) | ($9M) | ($1M) | ($1M) | Owner earningsOwner earn. |
| −15.5% | −11.6% | −24.8% | −6.2% | −6.2% | Owner earnings marginOE mgn |
| ($5M) | ($4M) | ($9M) | ($1M) | ($1M) | Free cash flowFCF |
| −15.5% | −11.6% | −24.8% | −6.2% | −6.2% | Free cash flow marginFCF mgn |
| — | 27% | 33% | -51% | -51% | ROICROIC |
| — | 30% | 32% | -88% | -88% | Return on equityROE |
| — | 30% | 32% | −88% | −88% | Retained to equityRetained/eq |
| Balance sheet | |||||
| — | — | $3M | $178K | $178K | Cash & investmentsCash+inv |
| — | $31M | $47M | $43M | $43M | ReceivablesReceiv. |
| — | $1M | $1M | $1M | $1M | InventoryInvent. |
| — | $550K | $1M | $2M | $2M | Accounts payablePayables |
| — | $32M | $47M | $42M | $42M | Operating working capitalOper. WC |
| — | $40M | $61M | $55M | $55M | Current assetsCur. assets |
| — | $19M | $35M | $32M | $32M | Current liabilitiesCur. liab. |
| — | 2.1× | 1.8× | 1.7× | 1.7× | Current ratioCurr. ratio |
| — | $59K | $58K | $60K | $60K | GoodwillGoodwill |
| — | $57M | $78M | $70M | $70M | Total assetsAssets |
| — | $2M | $4M | $9M | $9M | Total debtDebt |
| — | $2M | $1M | $9M | $9M | Net debt / (cash)Net debt |
| 45.6× | 41.7× | 26.6× | -34.8× | -34.8× | Interest coverageInt. cov. |
| — | $36M | $40M | $31M | $31M | Shareholders’ equityEquity |
| Per share | |||||
| 25.6M | 20.6M | 21.8M | 27.8M | 30.8M | Shares out (diluted)Shares |
| $1.37 | $1.53 | $1.70 | $0.81 | $0.73 | Revenue / shareRev/sh |
| $0.50 | $0.52 | $0.58 | $-0.99 | $-0.90 | EPS (diluted)EPS |
| $-0.21 | $-0.18 | $-0.42 | $-0.05 | $-0.05 | Owner earnings / shareOE/sh |
| $-0.21 | $-0.18 | $-0.42 | $-0.05 | $-0.05 | Free cash flow / shareFCF/sh |
| $0.23 | $0.13 | $0.13 | $0.00 | $0.00 | Cap. spending / shareCapex/sh |
| — | $1.74 | $1.82 | $1.13 | $1.02 | Book value / shareBVPS |
| 3-yr | 5-yr | |
|---|---|---|
| Revenue / share | −16.1%/yr | −16.1%/yr (3-yr) |
| Capital spending / share | −81.3%/yr | −81.3%/yr (3-yr) |
| Book value / share | −19.4%/yr (2-yr) | −19.4%/yr (2-yr) |
The record, charted
FY2022–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a $28M loss into ($1M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Reported net income | ($28M) | $13M | $11M | $13M |
| Depreciation & amortizationnon-cash charge added back | +$1M | +$1M | +$1M | +$916K |
| Working capital & othertiming of cash in and out, other non-cash items | +$25M | −$20M | −$13M | −$13M |
| Cash from operations | ($1M) | ($6M) | ($1M) | $486K |
| Capital expenditurecash put back in to keep running and to grow | −$42K | −$3M | −$3M | −$6M |
| Owner earnings | ($1M) | ($9M) | ($4M) | ($5M) |
| Owner-earnings marginowner earnings ÷ revenue | -6% | -25% | -12% | -15% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
“To remedy the identified material weaknesses, as of December 31, 2025, we had initiated the process of recruiting additional qualified accounting and financial reporting personnel with expertise in U.S.”
The figures below are only as sound as the controls that produced them. read the note →
Will it survive?
- Can it pay its interest? -34.8×Does not cover its interestOperating income ($26M) ÷ interest expense $737K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net debt against an operating lossCash $178K − debt $9M
What this means
Netting $178K of cash and short-term investments against $9M of debt leaves $9M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 689 + DIO 108 − DPO 180 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Very high (≥25%) through the cycle3-yr median, range -51%–33%; -51% latest = NOPAT ($20M) ÷ invested capital $40MIndustry peers: median -7%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 3 years (it ran -51% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Consumes cash through the cycle4-yr median margin, range -25%–-6%; latest ($1M) = operating cash ($1M) − maintenance capex $42KIndustry peers: median -5%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -6% of revenue this year, a -15% median across 4 years.
- Loss, and burning cashNet income ($28M) · cash from operations ($1M)
In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.04×HarvestingCapex $42K ÷ depreciation $1M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 1 of 3 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $23M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity NearCurrent ratio ≥ 2× · 1.70×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $9M vs $23M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.03/share (latest year $-0.67), the averaged base the calculator's gate runs on, and book value is $0.77/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2022–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 3 of 4
What this means
Lost money in 1 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 2 of 3 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 38% → −36% (2-yr avg ends)
What this means
Through the cycle the operating margin slipped — about 38% early to −36% lately, median 38% — competition or costs are biting in.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2025 · −113.7% op. margin
What this means
Operations went underwater in 2025, understand why before trusting the good years.
- Share count +2.8%/yr
What this means
The share count is rising, dilution works against you on a per-share basis.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product; it frames AI mainly as a capability.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$178K
- Receivables$43M
- Inventory$1M
- Other current assets$11M
- Debt due within a year$3M
- Accounts payable$2M
- Other current liabilities$28M
From the company's latest filing.
What an owner would ask, FY2025
read the 10-K →- How much of the revenue rides on one buyer?≈$5M · 23% of revenue on the largest customers (TTM)
“F- Customer concentration risk For the year ended December 31, 2025, two customers accounted for 23.3 % and 12.0 % of the Company's total revenue.”verify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Medical Devices & Equipment
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| NOCNorthrop Grumman Corporation | $42.0B | 71% | 11.4% | 16% | 8% |
| ROPRoper Technologies Inc. | $7.9B | 69% | 28.0% | 6% | 26% |
| IRTCiRhythm Technologies | $747M | 70% | -25.5% | -29% | -13% |
| TCMDTactile Systems Technology Inc. | $330M | 71% | 4.3% | 9% | 3% |
| HTFLHeartflow Inc. | $176M | 75% | -48.7% | -20% | -58% |
| BDMDBaird Medical Investment Holdings Ltd | $23M | 85% | 38.3% | 27% | -14% |
| NNNextNav Inc. | $5M | 40% | -1657.1% | -157% | -1066% |
| Group median | — | 71% | 4.3% | 6% | -13% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the home-market price, not the US ADR quote. Baird Medical Investment Holdings Ltd reports in USD, and every figure here (owner earnings, book value, the share count) is on that ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share. A US ADR price in dollars bundles the ADR-to-ordinary ratio, so it will not reconcile with these figures and would throw the multiple off.
Baird Medical Investment Holdings Ltd is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Revenue, delivered−11%/yr’22→’25
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← BCS its page in the Manual BEKE →
Industry order: ← BBNX the Medical Devices & Equipment chapter BDX →